GlassScriptPhysician profile
Colleen M Lustina
NPI 1346576998
$7,608.49
in general payments reported to CMS, 2019-2025
45 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,078 · 2022: $1,291 · 2023: $1,767 · 2024: $1,719 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,169 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,168.58 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,919.49 | 2021-2025 | |
| Novo Nordisk INC | $854.08 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $756.51 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $452.05 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $426.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $287.19 | 2021-2024 | Trintellix |
| Amgen INC. | $216.96 | 2021-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $211.94 | 2022-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $210.32 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $177.83 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $172.23 | 2022-2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.93 | 2022-2025 | Synjardy, Jardiance, Tradjenta |
| Phathom Pharmaceuticals, INC. | $135.56 | 2025 | Voquezna |
| Antares Pharma, INC. | $131.54 | 2021-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $122.68 | 2021-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $106.42 | 2022-2023 | Contrave, Nexletol |
| Abbott Laboratories | $101.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $94.78 | 2023-2024 | |
| Tris Pharma INC | $94.48 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $93.57 | 2021-2023 | Xarelto |
| Ironwood Pharmaceuticals, INC | $93.14 | 2021-2023 | Linzess |
| Bausch Health US, LLC | $78.03 | 2021-2022 | |
| Amarin Pharma, INC. | $66.18 | 2021-2022 | |
| Seqirus USA INC | $51.63 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Bioventus LLC | $49.19 | 2021-2023 | Durolane |
| Biohaven Pharmaceutical Holding Company LTD. | $49.08 | 2022 | |
| Glaxosmithkline, LLC. | $45.09 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $38.80 | 2023-2025 | |
| Esperion Therapeutics, INC. | $35.52 | 2021-2024 | Nexletol |
| Lundbeck LLC | $33.74 | 2024 | Vyepti |
| Philips North America LLC | $31.82 | 2024-2025 | (Ck7) Extended Holter, Mcot |
| Almatica Pharma LLC | $30.30 | 2025 | Loreev Xr |
| Biohaven Pharmaceuticals, INC. | $28.64 | 2021 | |
| Corcept Therapeutics | $28.46 | 2023 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.34 | 2025 | Caplyta |
| Depuy Synthes Sales INC. | $27.11 | 2021-2023 | Monovisc |
| Alfasigma USA, INC. | $25.54 | 2021 | |
| Sanofi Pasteur INC. | $23.72 | 2021 | |
| Organon LLC | $23.17 | 2025 | Nexplanon |
| Janssen Biotech, INC. | $22.82 | 2024 | Tremfya |
| Recordati_rare_diseases_inc. | $21.90 | 2025 | Isturisa |
| Organogenesis INC. | $19.97 | 2024 | Cygnus Dual |
| Noven Therapeutics, LLC | $16.47 | 2023 | Xelstrym |
| Cranial Technologies, INC | $13.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Lustina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.